

RANBAXY - Stretched Balance Sheet, a Weak Product Pipeline, and Uncertainty around Monetizing Exclusivities

https://marketpublishers.com/r/R51665FCBA6EN.html

Date: August 2013

Pages: 6

Price: US\$ 140.00 (Single User License)

ID: R51665FCBA6EN

Abstracts

Q2 CY-13 Result in Line: Sales grew by 8% QoQ primarily on account of higher Absorica (Isotretinoin) sales in US. US sales grew by 29% sequentially as company now has 14% share in Isotretinion (~\$400m market). Excluding US, revenue across the geographies remained muted and grew by 1% sequentially and 2% yoy.

EBITDA margin at 9.8%, has improved by 220 bps on sequential basis mainly due to high margin sales of Isotretinoin and INR depreciation. Forex loss of Rs.5403m and impairment of goodwill of Rs.1192m in France resulted in loss of Rs5242m at net level.



I would like to order

Product name: RANBAXY - Stretched Balance Sheet, a Weak Product Pipeline, and Uncertainty around

Monetizing Exclusivities

Product link: https://marketpublishers.com/r/R51665FCBA6EN.html

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/R51665FCBA6EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

